

# Ghazaleh Tabatabai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4091895/publications.pdf>

Version: 2024-02-01

109  
papers

6,687  
citations

93792

39  
h-index

75989

78  
g-index

117  
all docs

117  
docs citations

117  
times ranked

10072  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated <i>MGMT</i> promoter: An international randomized phase III trial. <i>Neuro-Oncology</i> , 2023, 25, 123-134.	0.6	150
2	The prognostic role of the immunohistochemical expression of S100 in meningiomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2975-2985.	1.2	2
3	Frequent <i>FGFR1</i> hotspot alterations in driver-unknown low-grade glioma and mixed neuronal-glioma tumors. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 857-866.	1.2	7
4	Tissue metabolites in diffuse glioma and their modulations by <i>IDH1</i> mutation, histology, and treatment. <i>JCI Insight</i> , 2022, 7, .	2.3	8
5	Gender disparity regarding work-life balance satisfaction among German neuro-oncologists: a YoungNOA survey. <i>Neuro-Oncology</i> , 2022, 24, 1609-1611.	0.6	1
6	MEDB-45. Functional genomics identifies epigenetic regulators as novel therapeutic targets for sonic hedgehog medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i116-i116.	0.6	0
7	ATRT-12. <i>LIN28A</i> expression correlates with poor prognosis and the <i>MYC</i> subgroup in AT/RTs. <i>Neuro-Oncology</i> , 2022, 24, i5-i5.	0.6	0
8	The role of Simpson grading in meningiomas after integration of the updated WHO classification and adjuvant radiotherapy. <i>Neurosurgical Review</i> , 2021, 44, 2329-2336.	1.2	18
9	Macrophage and Lymphocyte Infiltration Is Associated with Volumetric Tumor Size but Not with Volumetric Growth in the T4bingen Schwannoma Cohort. <i>Cancers</i> , 2021, 13, 466.	1.7	9
10	Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with <i>IDH1</i> -Mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 2723-2733.	3.2	33
11	A vaccine targeting mutant <i>IDH1</i> in newly diagnosed glioma. <i>Nature</i> , 2021, 592, 463-468.	13.7	232
12	Designing a SARS-CoV-2 T-Cell-Inducing Vaccine for High-Risk Patient Groups. <i>Vaccines</i> , 2021, 9, 428.	2.1	22
13	Differences in the expression of <i>SSTR1</i> in meningiomas and its therapeutic potential. <i>Neurosurgical Review</i> , 2021, , 1.	1.2	12
14	Loss of <i>H3K27me3</i> in meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1282-1291.	0.6	45
15	Targeting <i>CSF1R</i> Alone or in Combination with <i>PD1</i> in Experimental Glioma. <i>Cancers</i> , 2021, 13, 2400.	1.7	28
16	Glioma-Specific Diffusion Signature in Diffusion Kurtosis Imaging. <i>Journal of Clinical Medicine</i> , 2021, 10, 2325.	1.0	6
17	Argyris F Treatment-Induced Vulnerabilities Lead to a Novel Combination Therapy in Experimental Glioma. <i>Advanced Therapeutics</i> , 2021, 4, 2100078.	1.6	7
18	ADC-Based Stratification of Molecular Glioma Subtypes Using High <i>b</i> -Value Diffusion-Weighted Imaging. <i>Journal of Clinical Medicine</i> , 2021, 10, 3451.	1.0	7

#	ARTICLE	IF	CITATIONS
19	EANO guideline on the diagnosis and management of meningiomas. <i>Neuro-Oncology</i> , 2021, 23, 1821-1834.	0.6	230
20	H3K27me3 loss indicates an increased risk of recurrence in the TÅ¼bingen meningioma cohort. <i>Neuro-Oncology</i> , 2021, 23, 1273-1281.	0.6	34
21	Cerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients. <i>BMC Cancer</i> , 2021, 21, 1108.	1.1	5
22	FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma. <i>Neuro-Oncology Practice</i> , 2021, 8, 209-221.	1.0	7
23	BIOM-38. THE PROGNOSTIC ROLE OF THE IMMUNOHISTOCHEMICAL MARKERS H3K27me3, SSTR1-5 AND BAP1 IN MENINGIOMA. <i>Neuro-Oncology</i> , 2021, 23, vi19-vi19.	0.6	0
24	Increased proliferation is associated with CNS invasion in meningiomas. <i>Journal of Neuro-Oncology</i> , 2021, 155, 247-254.	1.4	6
25	A Continuous Correlation Between Residual Tumor Volume and Survival Recommends Maximal Safe Resection in Glioblastoma Patients: A Nomogram for Clinical Decision Making and Reference for Non-Randomized Trials. <i>Frontiers in Oncology</i> , 2021, 11, 748691.	1.3	6
26	A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma. <i>Journal of Neuro-Oncology</i> , 2020, 146, 79-89.	1.4	26
27	Depatux-M and temozolomide in advanced high-grade glioma. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa063.	0.4	1
28	Experimental glioma with high bHLH expression harbor increased replicative stress and are sensitive toward ATR inhibition. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa115.	0.4	2
29	Papillary tumor of the pineal region: a single-center experience. <i>Neuro-Oncology Practice</i> , 2020, 7, 384-390.	1.0	1
30	Glioblastoma: State of the Art and Future Perspectives. <i>Cancers</i> , 2019, 11, 1091.	1.7	7
31	Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial. <i>Journal of Neuro-Oncology</i> , 2019, 144, 501-509.	1.4	1
32	COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake. <i>Acta Neuropathologica Communications</i> , 2019, 7, 105.	2.4	17
33	Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. <i>Cancer Immunology Research</i> , 2019, 7, 1910-1927.	1.6	74
34	Corticosteroid-responsive aseptic meningitis during regorafenib treatment. <i>Neuro-Oncology Practice</i> , 2019, 6, 508-509.	1.0	2
35	Challenges and opportunities in meningiomas: recommendations from the International Consortium on Meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i2-i3.	0.6	7
36	Oncogenic KRAS hotspot mutations are rare in IDHâ€ mutant gliomas. <i>Brain Pathology</i> , 2019, 29, 321-324.	2.1	4

#	ARTICLE	IF	CITATIONS
37	Advances in multidisciplinary therapy for meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i18-i31.	0.6	102
38	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910.	0.6	184
39	Regorafenib in advanced high-grade glioma: a retrospective bicentric analysis. <i>Neuro-Oncology</i> , 2019, 21, 954-955.	0.6	15
40	Efficacy of systemic temozolomide-activated phage-targeted gene therapy in human glioblastoma. <i>EMBO Molecular Medicine</i> , 2019, 11, .	3.3	51
41	Measles Virus-Based Treatments Trigger a Pro-inflammatory Cascade and a Distinctive Immunopeptidome in Glioblastoma. <i>Molecular Therapy - Oncolytics</i> , 2019, 12, 147-161.	2.0	38
42	Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA09): a randomised, open-label, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 678-688.	6.3	384
43	Longitudinal molecular trajectories of diffuse glioma in adults. <i>Nature</i> , 2019, 576, 112-120.	13.7	320
44	Retrospective analysis of fractionated intensity-modulated radiotherapy (IMRT) in the interdisciplinary management of primary optic nerve sheath meningiomas. <i>Radiation Oncology</i> , 2019, 14, 240.	1.2	25
45	High frequency of H3 K27M mutations in adult midline gliomas. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 839-850.	1.2	50
46	Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 975-985.	0.6	11
47	Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. <i>Neuro-Oncology</i> , 2018, 20, 367-379.	0.6	79
48	MNGI-11. LONGITUDINAL GENOMIC ANALYSIS OF SPORADIC MENINGIOMAS WITH MULTIPLE RECURRENCES. <i>Neuro-Oncology</i> , 2018, 20, vi150-vi150.	0.6	0
49	ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIOTHERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL. <i>Neuro-Oncology</i> , 2018, 20, vi14-vi14.	0.6	0
50	DRES-05. MOLECULAR EVOLUTION OF DIFFUSE GLIOMAS AND THE GLIOMA LONGITUDINAL ANALYSIS CONSORTIUM. <i>Neuro-Oncology</i> , 2018, 20, vi76-vi76.	0.6	0
51	Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma. <i>Oncologist</i> , 2017, 22, 570-575.	1.9	23
52	The Prognostic Impact of Ventricular Opening in Glioblastoma Surgery: A Retrospective Single Center Analysis. <i>World Neurosurgery</i> , 2017, 106, 615-624.	0.7	19
53	Risk Factors of Preoperative and Early Postoperative Seizures in Patients with Meningioma: A Retrospective Single-Center Cohort Study. <i>World Neurosurgery</i> , 2017, 97, 538-546.	0.7	37
54	MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 823-833.	1.9	36

#	ARTICLE	IF	CITATIONS
55	PI3K Pathway Inhibition Achieves Potent Antitumor Activity in Melanoma Brain Metastases <i>In Vitro</i> and <i>In Vivo</i> . <i>Clinical Cancer Research</i> , 2016, 22, 5818-5828.	3.2	68
56	Limited role for transforming growth factor- $\beta$ pathway activation-mediated escape from VEGF inhibition in murine glioma models. <i>Neuro-Oncology</i> , 2016, 18, 1610-1621.	0.6	27
57	ATRX immunostaining predicts IDH and H3F3A status in gliomas. <i>Acta Neuropathologica Communications</i> , 2016, 4, 60.	2.4	100
58	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial. <i>Neuro-Oncology</i> , 2016, 18, 549-556.	0.6	187
59	The role of integrins in primary and secondary brain tumors. <i>Histology and Histopathology</i> , 2016, 31, 1069-78.	0.5	8
60	Predictors of preoperative and early postoperative seizures in patients with intra-axial primary and metastatic brain tumors: A retrospective observational single center study. <i>Annals of Neurology</i> , 2015, 78, 917-928.	2.8	60
61	Differential regulation of TGF- $\beta$ -induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 254-265.	0.6	65
62	<i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2057-2064.	3.2	264
63	In vivo visualization of prostate-specific membrane antigen in glioblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 170-171.	3.3	85
64	The management of lomustine overdose in malignant glioma patients. <i>Neuro-Oncology Practice</i> , 2014, 1, 178-183.	1.0	9
65	Targeting the bHLH Transcriptional Networks by Mutated E Proteins in Experimental Glioma. <i>Stem Cells</i> , 2014, 32, 2583-2595.	1.4	4
66	Thymosin beta 4 gene silencing decreases stemness and invasiveness in glioblastoma. <i>Brain</i> , 2014, 137, 433-448.	3.7	44
67	Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. <i>Journal of Neuro-Oncology</i> , 2014, 117, 141-145.	1.4	52
68	<i>MGMT</i> promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 2015-2015.	0.8	6
69	Acid sphingomyelinase-ceramide system mediates effects of antidepressant drugs. <i>Nature Medicine</i> , 2013, 19, 934-938.	15.2	313
70	Integrin control of the transforming growth factor- $\beta$ pathway in glioblastoma. <i>Brain</i> , 2013, 136, 564-576.	3.7	94
71	Prognostic or predictive value of <i>MGMT</i> promoter methylation in gliomas depends on <i>IDH1</i> mutation. <i>Neurology</i> , 2013, 81, 1515-1522.	1.5	211
72	Multimodal Elucidation of Choline Metabolism in a Murine Glioma Model Using Magnetic Resonance Spectroscopy and $^{11}\text{C}$ -Choline Positron Emission Tomography. <i>Cancer Research</i> , 2013, 73, 1470-1480.	0.4	32

#	ARTICLE	IF	CITATIONS
73	Deletion of the ageing gene p66Shc reduces early stroke size following ischaemia/reperfusion brain injury. <i>European Heart Journal</i> , 2013, 34, 96-103.	1.0	72
74	Malignant astrocytoma in elderly patients. <i>Current Opinion in Neurology</i> , 2013, 26, 693-700.	1.8	7
75	Targeting hyperactivation of the <scp>AKT</scp> survival pathway to overcome therapy resistance of melanoma brain metastases. <i>Cancer Medicine</i> , 2013, 2, 76-85.	1.3	126
76	Glioma Cell Death Induced by Irradiation or Alkylating Agent Chemotherapy Is Independent of the Intrinsic Ceramide Pathway. <i>PLoS ONE</i> , 2013, 8, e63527.	1.1	18
77	The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , 2013, 31, e20050-e20050.	0.8	2
78	Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma (DIRECTOR).. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS2103-TPS2103.	0.8	0
79	Effect of silencing thymosin beta 4 gene expression on stemness and invasiveness in glioblastoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2081-2081.	0.8	0
80	Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomography. <i>Neuro-Oncology</i> , 2012, 14, 471-481.	0.6	9
81	Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 707-715.	5.1	980
82	HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. <i>Journal of Neuroimmunology</i> , 2012, 250, 27-34.	1.1	39
83	Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 302-307.	2.0	21
84	Effect of the integrin inhibitor cilengitide on TGF-beta signaling.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2055-2055.	0.8	42
85	Bevacizumab failure in glioblastomas.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2067-2067.	0.8	2
86	Bevacizumab plus radiotherapy for elderly patients with glioblastoma (ARTE).. <i>Journal of Clinical Oncology</i> , 2012, 30, TPS2105-TPS2105.	0.8	1
87	Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8526-8526.	0.8	0
88	CAMTA1 is a novel tumour suppressor regulated by miR-9/9<sup>*</sup> in glioblastoma stem cells. <i>EMBO Journal</i> , 2011, 30, 4309-4322.	3.5	141
89	Glioblastoma stem cells. <i>Cell and Tissue Research</i> , 2011, 343, 459-465.	1.5	75
90	APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. <i>Neuro-Oncology</i> , 2011, 13, 155-164.	0.6	42

#	ARTICLE	IF	CITATIONS
91	The Role of Integrins in Glioma Biology and Anti-Glioma Therapies. <i>Current Pharmaceutical Design</i> , 2011, 17, 2402-2410.	0.9	39
92	Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. <i>Journal of Neurosurgery</i> , 2010, 113, 280-285.	0.9	30
93	Molecular diagnostics of gliomas: the clinical perspective. <i>Acta Neuropathologica</i> , 2010, 120, 585-592.	3.9	127
94	Targeting integrins in malignant glioma. <i>Targeted Oncology</i> , 2010, 5, 175-181.	1.7	83
95	GDF-15 Contributes to Proliferation and Immune Escape of Malignant Gliomas. <i>Clinical Cancer Research</i> , 2010, 16, 3851-3859.	3.2	125
96	Glioma tropism of lentivirally transduced hematopoietic progenitor cells. <i>International Journal of Oncology</i> , 2010, 36, 1409-17.	1.4	10
97	Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?. <i>Future Oncology</i> , 2010, 6, 1407-1414.	1.1	23
98	Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. <i>Neuro-Oncology</i> , 2009, 11, 747-756.	0.6	79
99	Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival. <i>Modern Pathology</i> , 2009, 22, 1600-1611.	2.9	24
100	Primetime for antiangiogenic therapy. <i>Current Opinion in Neurology</i> , 2009, 22, 639-644.	1.8	9
101	Enzastaurin-induced apoptosis in glioma cells is caspase-dependent and inhibited by BCL <sub>L</sub> . <i>Journal of Neurochemistry</i> , 2008, 106, 2436-2448.	2.1	26
102	VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells. <i>Brain</i> , 2008, 131, 2579-2595.	3.7	21
103	Vertebral artery dissection presenting with ipsilateral acute C5 and C6 sensorimotor radiculopathy: A case report. <i>Cases Journal</i> , 2008, 1, 139.	0.4	18
104	Synergistic antiglioma activity of radiotherapy and enzastaurin. <i>Annals of Neurology</i> , 2007, 61, 153-161.	2.8	72
105	Expression pattern of the water channel aquaporin-4 in human gliomas is associated with blood-brain barrier disturbance but not with patient survival. <i>Journal of Neuroscience Research</i> , 2007, 85, 1336-1346.	1.3	120
106	Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells. <i>Journal of Neuroimmunology</i> , 2007, 189, 50-58.	1.1	56
107	Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF- $\beta$ -dependent HIF-1A-mediated induction of CXCL12. <i>Brain</i> , 2006, 129, 2426-2435.	3.7	116
108	Primary Amyloidoma of the Brain Parenchyma. <i>Archives of Neurology</i> , 2005, 62, 477.	4.9	25

#	ARTICLE	IF	CITATIONS
109	Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. <i>Brain</i> , 2005, 128, 2200-2211.	3.7	77